<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>66(7)</volume><submitter>De la Rosa SO</submitter><pubmed_abstract>&lt;h4>Objective&lt;/h4>Biallelic pathogenic MBOAT7 variants are associated with neurodevelopmental disorders, intellectual disability (ID), epilepsy, and neuropsychiatric disorders such as attention-deficit/hyperactivity disorder and autism spectrum disorders. We aimed to characterize the epilepsy phenotype in a cohort of patients affected by this syndrome.&lt;h4>Methods&lt;/h4>We describe epilepsy features, electroencephalography, magnetic resonance imaging (MRI) findings, antiseizure treatment response, and neurodevelopment of 15 patients with biallelic MBOAT7 variants.&lt;h4>Results&lt;/h4>All 15 patients had ID or developmental delay (DD). Twelve suffered from epilepsy, with mean age at seizure onset of 36 months (range = 2 months-6.5 years) and 10 of 12 showing signs of DD before seizure onset. Patien</pubmed_abstract><journal>Epilepsia</journal><pagination>2379-2390</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12291024</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>MBOAT7 encephalopathy: Characterizing the neurology and epileptology.</pubmed_title><pmcid>PMC12291024</pmcid><pubmed_authors>Costa C</pubmed_authors><pubmed_authors>Nunes T</pubmed_authors><pubmed_authors>Jauss RT</pubmed_authors><pubmed_authors>Boerkoel CF</pubmed_authors><pubmed_authors>Gavrilova R</pubmed_authors><pubmed_authors>Ahrens-Nicklas R</pubmed_authors><pubmed_authors>Ortigoza-Escobar JD</pubmed_authors><pubmed_authors>Gardella E</pubmed_authors><pubmed_authors>Sherr E</pubmed_authors><pubmed_authors>Platzer K</pubmed_authors><pubmed_authors>De la Rosa SO</pubmed_authors><pubmed_authors>Koolen DA</pubmed_authors><pubmed_authors>Huynh S</pubmed_authors><pubmed_authors>Fenger CD</pubmed_authors><pubmed_authors>Prontera P</pubmed_authors><pubmed_authors>Rakic B</pubmed_authors><pubmed_authors>Argilli E</pubmed_authors><pubmed_authors>Lemire G</pubmed_authors><pubmed_authors>Casas-Alba D</pubmed_authors><pubmed_authors>Huh L</pubmed_authors><pubmed_authors>Bartolomaeus T</pubmed_authors><pubmed_authors>Rizzo V</pubmed_authors><pubmed_authors>Mercimek-Andrews S</pubmed_authors><pubmed_authors>Moller RS</pubmed_authors><pubmed_authors>Bayat A</pubmed_authors><pubmed_authors>Khinchi MS</pubmed_authors><pubmed_authors>Bernard G</pubmed_authors><pubmed_authors>Escolar M</pubmed_authors><pubmed_authors>Boycott KM</pubmed_authors></additional><is_claimable>false</is_claimable><name>MBOAT7 encephalopathy: Characterizing the neurology and epileptology.</name><description>&lt;h4>Objective&lt;/h4>Biallelic pathogenic MBOAT7 variants are associated with neurodevelopmental disorders, intellectual disability (ID), epilepsy, and neuropsychiatric disorders such as attention-deficit/hyperactivity disorder and autism spectrum disorders. We aimed to characterize the epilepsy phenotype in a cohort of patients affected by this syndrome.&lt;h4>Methods&lt;/h4>We describe epilepsy features, electroencephalography, magnetic resonance imaging (MRI) findings, antiseizure treatment response, and neurodevelopment of 15 patients with biallelic MBOAT7 variants.&lt;h4>Results&lt;/h4>All 15 patients had ID or developmental delay (DD). Twelve suffered from epilepsy, with mean age at seizure onset of 36 months (range = 2 months-6.5 years) and 10 of 12 showing signs of DD before seizure onset. Patien</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Jul</publication><modification>2025-08-13T03:04:11.622Z</modification><creation>2025-08-13T03:04:11.622Z</creation></dates><accession>S-EPMC12291024</accession><cross_references><pubmed>40116760</pubmed><doi>10.1111/epi.18376</doi></cross_references></HashMap>